These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31775736)

  • 1. Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria.
    Tkachova O; Iakovlieva L; Mitkova Z; Manova M; Savova A; Petrova G
    BMC Health Serv Res; 2019 Nov; 19(1):902. PubMed ID: 31775736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price and utilisation differences for statins between four countries.
    Thai LP; Vitry AI; Moss JR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):71-81. PubMed ID: 28800399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affordability of medicines in the European Union.
    Zaprutko T; Kopciuch D; Kus K; Merks P; Nowicka M; Augustyniak I; Nowakowska E
    PLoS One; 2017; 12(2):e0172753. PubMed ID: 28241019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug affordability-potential tool for comparing illicit drug markets.
    Groshkova T; Cunningham A; Royuela L; Singleton N; Saggers T; Sedefov R
    Int J Drug Policy; 2018 Jun; 56():187-196. PubMed ID: 29459212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis.
    Selvaraj S; Farooqui HH; Mehta A
    BMJ Open; 2019 Jan; 9(1):e024200. PubMed ID: 30679294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policy implications of rationalization of statin use in Lithuania.
    Kadusevicius E; Jankauskiene D; Paulauskaite I; Slapikas R
    Int J Technol Assess Health Care; 2009 Jul; 25(3):419-24. PubMed ID: 19619363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics.
    Son KB
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):541-548. PubMed ID: 31483158
    [No Abstract]   [Full Text] [Related]  

  • 12. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability, prices and affordability of essential medicines for children: a cross-sectional survey in Jiangsu Province, China.
    Sun X; Wei J; Yao Y; Chen Q; You D; Xu X; Dai J; Yao Y; Sheng J; Li X
    BMJ Open; 2018 Oct; 8(10):e023646. PubMed ID: 30341137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
    Lee L; Kim H
    Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has cost inhibited the uptake of more potent statins in England?
    Chapman SR; Fitzpatrick RW; Aladul MI
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and economics of statin use.
    Feely J; Bennett K
    Ir Med J; 2008 Jun; 101(6):188-91. PubMed ID: 18705057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability, prices and affordability of selected antibiotics and medicines against non-communicable diseases in western Cameroon and northeast DR Congo.
    Schäfermann S; Neci R; Ndze EN; Nyaah F; Pondo VB; Heide L
    PLoS One; 2020; 15(1):e0227515. PubMed ID: 31910444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.